The US Food and Drug Administration announced this week that after a national search the agency has decided to stick with its own Janet Woodcock, as the permanent director of the agency's Center for Drug Evaluation and Research.
While serving as the agency's deputy commissioner and chief medical officer, Woodcock assumed the role of acting director of CDER in October 2007. As director of CDER, a position she previously held for a decade, Woodcock’s overarching responsibility will be to ensure the safety and effectiveness of prescription, over-the-counter, and generic drugs.
Woodcock has held several positing in her time at the FDA, including director of the Office of Therapeutics Research and Review, and acting deputy director of the Center for Biologics Evaluation and Research. She has also received numerous awards, including a Presidential Rank Meritorious Executive Award, the Personalized Medicine Coalition's Award for Leadership in Personalized Medicine, and six Special Citations from FDA Commissioners.
Invitrogen has agreed to give CEO Greg Lucier an increase in his base salary to $975,000, according to a filing with the US Securities and Exchange Commission. The change was approved by the firm’s board of directors on Feb. 27 and is retroactive to Jan. 1, 2008.
J. Craig Venter will spend the next year as a visiting scholar at Harvard University in the Origins of Life Initiative.
Venter started the one-year appointment at the beginning of March. Dimitar Sasselov, the initiative’s director, said Venter will work on “the big questions that lie beyond the horizon of the current successes in synthetic genomics and synthetic biology.”